This is the first single-center, real-world study describing the occurrence of endocrine and non-endocrine irAEs following use of CTLA4, PD-1 and PD-L1 inhibitors in a broad range of solid tumor malignancies and to investigate their association with cancer survival. The gene discussed is CTLA4; the disease is cancer.